Shares of DataMEDS AI Inc. (NASDAQ:MEDS) are trading sharply higher Wednesday morning as investors digest the completed acquisition of an AI-driven cancer diagnostics platform and contract research organization business.
- DataMEDS AI stock is at critical resistance. Why is MEDS stock breaking out?
Completed Helomics Acquisition Adds CLIA Lab Assets and $1.5M Cash
On Tuesday, DataMEDS announced it completed the acquisition of artificial intelligence cancer diagnostics laboratory business Helomics Corporation from neocloud AI infrastructure provider Axe Compute Inc. (NASDAQ:AGPU).
Under the agreement, DataMEDS acquired Helomics, inclusive of its CLIA/CAP-certified clinical laboratory, Predictive Oncology CRO central lab services and $1.5 million in cash, in exchange for common shares and an acquisition note totaling a purchase value of $1.5 million. The acquired entity carries zero third-party debt and no outstanding accounts payable outside of regular monthly operating expenses.
Helomics, a Pittsburgh-based functional precision medicine oncology platform, applies AI to real-world tumor data and represents the final remaining operating unit from Axe Compute’s former identity as Predictive Oncology Inc.
Management Positions Acquisition to Expand Healthcare Ecosystem
The transaction marks DataMEDS’ strategic expansion into the $40 billion U.S. cancer diagnostic and treatment market, broadening its clinical focus beyond GLP-1 agonist side-effect management and long COVID care.
Highlighting the clinical significance, Gerald Commissiong, Interim Co-CEO of DataMEDS, stated: “We are thrilled to have completed this strategic transaction that thrusts DataMEDS into the field of oncology, where we know there is a tremendous need to improve patient outcomes, especially in rural areas.”
Chris Miglino, CEO of Axe Compute, noted that Axe Compute was pleased to maintain an equity stake in “the future of AI Helomics” while sharpening its own operational focus on scaling core GPU-as-a-Service infrastructure.
MEDS Stock Skyrockets Wednesday Morning
MEDS Price Action: DataMEDS AI shares were up 253.70% at $5.73 at the time of publication on Wednesday. The stock is trading at a new 52-week high, according to Benzinga Pro data.
Image: Shutterstock
Login to comment